Radiotherapy Market, estimated at $6.9 billion in 2023, is forecasted to hit $8.8 billion by 2028, expanding at a CAGR of 5.0%. This market report delves into industry trends, including pricing analysis, patents, and insights from conferences and webinars. The market’s growth is influenced by the rising global cancer burden and innovations like MRI linear accelerators and proton therapy, which improve cancer treatment outcomes. Increased awareness about early tumor detection, along with government investments in new radiotherapy technologies and the construction of cancer treatment centers, will further drive market growth.
Download an Illustrative overview
The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023.
Based on procedure, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy. The external beam radiotherapy segment dominated this market with a share of in 2022. The large share of this segment can primarily be attributed to the reduced risk of radiation exposure in external beam radiotherapy and the increased precision & accuracy of tumor targeting in this therapy.
This external beam radiotherapy (EBRT) technique is widely preferred over other therapeutic techniques such as brachytherapy and systemic radiotherapy due to its wide range of benefits, including lesser side effects and cost-effectiveness. Moreover, continuous EBRT technological advancements such as MRI Linac, particle therapy and rising research activities in the field of radiation oncology using proton therapy systems are likely to support the growth of the segment
Hospitals were the key end-users in the radiotherapy market
Based on end user, the radiotherapy market has been segmented into hospitals and independent radiotherapy centers. Hospitals commanded the largest share of the global radiotherapy systems market in 2023. Rising initiatives by government to upgrade hospitals with advanced radiotherapy devices, rising collaborations among cancer hospital and radiotherapy device manufacturers, and increasing number of cancer patients undergoing radiotherapy treatment procedures in hospitals
“The APAC market, by region, to register highest growth rate in the forecast period.”
On the basis of region, the radiotherapy market is segmented into North America, Europe, Asia Pacific, and the Latin America, Middle East & Africa. The Asia-Pacific market is likely witnessing significant growth owing to increase in cancer patient pool, improving healthcare infrastructure and the implementation of supportive government initiatives in several APAC countries such as India and China. The rising geriatric population, growing incidence of cancer, and the rising acceptance of radiotherapy procedures and devices are the other major factors driving market growth in Asia Pacific. Additionally rising medical tourism and entry of major market players in the Asia Pacific countries are likely to support the radiotherapy market growth in APAC.
Radiotherapy Market Dynamics:
Drivers:
- Technological advancements in radiotherapy treatment
Restraints:
- lack of adequate healthcare infrastructure in emerging countries
Opportunities:
- Rising Healthcare Expenditure Across Developing Countries
Challenge:
- Risk of Radiation Exposure
Key Market Players of Radiotherapy Industry:
As of 2022, the automated radiation therapy systems market was dominated by Siemens Healthineers AG (Germany), Varian Medical Systems, Inc. (US), Elekta (Sweden) Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), Hitachi Ltd. (Japan), iCAD, Inc. (US), IsoRay, Inc. (US), among others.
Recent Developments:
- In October 2023, Accuray incorporated received approval of Tomo C radiation therapy system by the Chinese National Medical Products Administration (NMPA).
- In July 2023, IBA entered into partnership with Apollo Proton Cancer Centre (APCC) (India) to provide training to Oncologist on proton beam therapy
- In April 2022, Elekta and GE HealthCare entered into a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Content Source:
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
